Bank Of New York Mellon Corp Lipocine Inc. Transaction History

Bank Of New York Mellon Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.37 - $8.65 $19,595 - $458,104	52,960 New	52,960 $21,000
Q2 2022 Aug 15, 2022	SELL	$0.73 - $1.34 $1,638 - $3,006	-2,244 Reduced 4.06%	52,960 $42,000
Q3 2021 Nov 12, 2021	SELL	$1.08 - $1.49 $59,400 - $81,950	-55,000 Reduced 49.91%	55,204 $60,000
Q2 2021 Aug 11, 2021	BUY	$1.17 - $1.59 $64,349 - $87,450	55,000 Added 99.63%	110,204 $154,000
Q1 2021 May 13, 2021	SELL	$1.38 - $2.28 $7,841 - $12,954	-5,682 Reduced 9.33%	55,204 $83,000
Q4 2020 Feb 09, 2021	BUY	$1.2 - $1.69 $56,445 - $79,494	47,038 Added 339.67%	60,886 $82,000
Q2 2019 Aug 12, 2019	SELL	$1.43 - $2.32 $400 - $649	-280 Reduced 1.98%	13,848 $27,000
Q1 2019 May 14, 2019	SELL	$1.46 - $2.33 $204 - $326	-140 Reduced 0.98%	14,128 $33,000
Q2 2018 Aug 06, 2018	SELL	$1.06 - $1.78 $28,397 - $47,686	-26,790 Reduced 65.25%	14,268 $19,000
Q1 2018 May 15, 2018	SELL	$1.18 - $3.46 $8,461 - $24,811	-7,171 Reduced 14.87%	41,058 $62,000
Q4 2017 Feb 09, 2018	BUY	$3.36 - $4.35 $162,049 - $209,796	48,229	48,229 $166,000

Ticker LPCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,510,800
Market Cap $431M
Description
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.